Skip to main content

Table 2 Univariate and multivariable analyses of factors associated with time to treatment failure, progression-free-survival, and overall survival

From: Prognostic model for overall survival that includes the combination of platelet count and neutrophil–lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma

Variables

Time to treatment failure

Progression-free-survival

Overall survival

Univariate

Multivariableb

Univariate

Multivariablec

Univariate

Multivariabled

HR

P

HR

P

HR

P

HR

P

HR

P

HR

P

(β)

(β)

(β)

Characteristics

 Sex (female vs. male)

0.987

0.960

  

1.115

0.682

  

0.890

0.734

  

 Age (≥ 65 vs. < 65 years)

1.624

0.024

  

1.256

0.290

  

0.822

0.474

  

 ECOG PS (≥ 2 vs. 0, 1)

1.520

0.165

  

1.452

0.216

  

2.599

0.012

  

 MSKCC risk group (poor vs. others)

2.934

 < 0.001

  

3.340

 < 0.001

3.234

 < 0.001

9.115

 < 0.001

7.239

 < 0.001

(1.174)

(1.979)

 Prior nephrectomy (yes vs. no)

0.651

0.071

  

0.650

0.068

  

0.308

 < 0.001

  

 Number of metastatic sites (≥ 2 vs. 0, 1)

1.960

0.002

2.322

 < 0.001

2.369

 < 0.001

2.273

 < 0.001

2.756

0.001

3.260

 < 0.001

(0.842)

(0.821)

(1.182)

 Treatment (2, 3 vs. 1st line)

1.023

0.921

  

1.188

0.455

  

1.131

0.687

  

 6-week RDI (< 60 vs. ≥ 60%)

2.671

 < 0.001

3.160

 < 0.001

1.321

0.190

  

1.581

0.095

  

(1.151)

 Duration of therapy (< 6 vs. ≥ 6 weeks)

  

2.375

 < 0.001

  

2.088

0.014

  

Adverse eventsa

 Hypertension (no vs. yes)

1.371

0.136

  

1.194

0.412

  

2.169

0.005

2.073

0.024

(0.729)

 Hand-foot syndrome (no vs. yes)

1.537

0.046

  

1.529

0.049

1.664

0.043

1.203

0.499

  

(0.509)

 Diarrhea (no vs. yes)

0.668

0.080

  

0.673

0.087

  

0.563

0.047

1.903

0.066

(0.643)

 Hypothyroidism (no vs. yes)

1.495

0.099

  

1.414

0.154

  

1.085

0.790

  

 Leukopenia (no vs. yes)

0.832

0.389

  

0.650

0.047

  

0.704

0.206

  

 Thrombocytopenia (no vs. yes)

1.263

0.350

  

0.942

0.814

  

1.649

0.112

  

 Elevation of ALP (no vs. yes)

0.740

0.159

  

0.695

0.093

  

0.457

0.007

  

Laboratory data at start of sunitinib

 Hb (≥ 12 vs. < 12 g/dL)

0.504

0.001

  

0.514

0.002

  

0.280

 < 0.001

  

 Ca (≥ 10 vs. < 10 g/dL)

1.841

0.029

  

1.987

0.017

  

4.009

 < 0.001

  

 LDH (> 333 vs. ≤ 333 U/L)

5.395

 < 0.001

  

7.278

 < 0.001

  

14.550

 < 0.001

  

 AST (> 30 vs. ≤ 30 U/L)

2.160

0.003

2.303

0.009

2.060

0.006

  

2.689

0.002

  

(0.834)

 Alb (≥ 3.5 vs. < 3.5 g/dL)

0.550

0.008

  

0.469

0.001

  

0.225

 < 0.001

  

 CRP (> 0.5 vs. ≤ 0.5 g/dL)

2.239

 < 0.001

  

2.055

0.001

  

4.465

 < 0.001

  

 ALP (> 322 vs. ≤ 322 U/L)

2.102

 < 0.001

1.811

0.013

2.253

 < 0.001

  

3.134

 < 0.001

  

(0.594)

 mGPS (1, 2 vs. 0)

2.037

0.001

  

2.134

 < 0.001

  

5.119

 < 0.001

2.946

0.005

(1.080)

 NLR (> 3.5 vs. ≤ 3.5)

1.319

0.207

  

1.519

0.059

  

3.080

 < 0.001

  

 PLT (> 310 vs. ≤ 310 × 109 /L)

1.318

0.223

  

1.457

0.098

  

2.290

0.005

  

 COP-NLR (1, 2 vs. 0)

1.271

0.256

  

1.327

0.184

  

2.823

 < 0.001

  

Laboratory data within the first 6 weeks of sunitinib

 Hb (≥ 12 vs. < 12 g/dL)

0.611

0.020

  

0.507

0.002

  

0.270

 < 0.001

  

 Ca (≥ 10 vs. < 10 g/dL)

3.798

 < 0.001

  

3.639

 < 0.001

  

5.053

 < 0.001

  

 LDH (> 333 vs. ≤ 333 U/L)

2.218

0.001

  

2.397

 < 0.001

  

3.531

 < 0.001

  

 AST (> 30 vs. ≤ 30 U/L)

1.311

0.202

  

1.414

0.107

  

1.185

0.536

  

 Alb (≥ 3.5 vs. < 3.5 g/dL)

0.527

0.003

  

0.510

0.002

  

0.396

0.001

  

 CRP (> 0.5 vs. ≤ 0.5 g/dL)

1.732

0.026

  

1.718

0.034

  

1.421

0.286

  

 mGPS (1, 2 vs. 0)

1.749

0.026

  

1.765

0.030

  

1.348

0.366

  

 NLR (> 3.5 vs. ≤ 3.5)

2.898

 < 0.001

  

2.799

 < 0.001

  

4.357

 < 0.001

  

 PLT (> 310 vs. ≤ 310 × 109 /L)

5.578

 < 0.001

  

5.142

 < 0.001

  

7.758

 < 0.001

  

 COP-NLR (1, 2 vs. 0)

2.898

 < 0.001

2.255

0.003

2.799

 < 0.001

2.270

0.004

4.357

 < 0.001

2.860

0.002

(0.813)

(0.820)

(1.051)

  1. aAdverse events were developed within the first 6 weeks of sunitinib. HR Hazard ratio, β Beta-coefficient, ECOG PS Eastern Cooperative Oncology Group Performance Status, MSKCC Memorial Sloan Kettering Cancer Center, RDI Relative Dose Intensity, Hb Hemoglobin, Ca Calcium, LDH Lactate dehydrogenase, AST Aspartate aminotransferase, Alb Albumin, CRP C-reactive protein, ALP Alkaline phosphatase, mGPS Modified Glasgow Prognostic Score, NLR Neutrophil–lymphocyte ratio, PLT Platelet count, COP-NLR Combination of platelet count and neutrophil– lymphocyte ratio
  2. bAge, MSKCC risk group, number of metastatic sites, hand-foot syndrome, 6-week RDI, AST, ALP, mGPS, 6-week mGPS, and 6-week COP-NLR were subjected to multivariate analysis
  3. cMSKCC risk group, number of metastatic sites, duration of therapy, hand-foot syndrome, leukopenia, mGPS, AST, ALP, 6-week mGPS, and 6-week COP-NLR were subjected to multivariate analysis
  4. dMSKCC risk group, prior nephrectomy, number of metastatic sites, duration of therapy, hypertension, diarrhea, elevation of ALP, AST, ALP, mGPS, COP-NLR, 6-week Alb, and 6-week COP-NLR were subjected to multivariate analysis